Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Alteplase→

Alteplase PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
105857-23-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant tissue-type plasminogen activator (rt-PA)fibrinolytic thrombolytic agent
Mechanism of action
A serine protease that catalyses conversion of plasminogen to plasmin. Activation is enhanced in the presence of fibrin, promoting degradation of fibrin-rich thrombi.
Indications / reported uses
  • Acute ischaemic stroke in appropriately selected patients within the product-specific treatment window
  • Acute myocardial infarction and acute massive pulmonary embolism in selected clinical settings
  • Restoration of function to central venous access devices occluded by thrombus with the low-dose catheter-lock formulation; indications and dosing are formulation-specific

Sources: US DailyMed — Activase (alteplase) · US FDA prescribing information — Activase · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Recombinant tissue-type plasminogen activator (rt-PA); fibrinolytic thrombolytic agent

Mechanism of action

A serine protease that catalyses conversion of plasminogen to plasmin. Activation is enhanced in the presence of fibrin, promoting degradation of fibrin-rich thrombi.

General use cases

  • Acute ischaemic stroke in appropriately selected patients within the product-specific treatment window
  • Acute myocardial infarction and acute massive pulmonary embolism in selected clinical settings
  • Restoration of function to central venous access devices occluded by thrombus with the low-dose catheter-lock formulation; indications and dosing are formulation-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Alteplase PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Alteplase Permitted Daily Exposure (PDE) report (the Alteplase PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Alteplase Occupational Exposure Limit (OEL) report (the Alteplase OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.